FDA Approves Onivyde Combination for Metastatic Pancreatic Cancer
Approval allows Onivyde (plus oxaliplatin, fluorouracil, and leucovorin) as first-line therapy
Type 2 Diabetes Remission Maintained After RYGB Despite Weight Regain
Overall rate of continued diabetes remission higher for those undergoing RYGB versus sleeve gastrectomy
Link Between Inflammatory Disease, Adverse Pregnancy Outcomes Varies
Patients with IMIDs had increased risk for PTB, LBW, SGA, C-section overall, but variation seen by disease, comorbidities
Fruquintinib + Paclitaxel Aids Advanced Gastric/Gastroesophageal Junction Cancer
Improvement seen in progression-free survival among patients who had disease progression on first-line chemotherapy
NASH Resolution Increased, Improvement of Fibrosis Seen With Resmetirom
Resmetirom 80 mg and 100 mg better than placebo for patients with NASH and fibrosis stage F1B, F2, F3
CDC Investigating Illness Outbreak on Luxury Cruise Ship
BP Control Improved With Gastric Bypass in Patients With Obesity, Hypertension
Significantly higher rate seen for number of medications with at least a 30 percent reduction
Price of Prescription Drugs Almost Threefold Higher in the United States
U.S. prices for brand-name originator drugs 422 percent higher; price of unbranded generics 67 percent of comparison countries
Rate of Venous Thromboembolism Increased With Cancer Surgery
Cause-specific hazard ratio for pulmonary embolism peaked after discharge, then plateaued 60 to 90 days later
Missed, Undiagnosed Cirrhosis May Be Risk Factor for Cognitive Decline
More than 5 percent of veterans with dementia had Fibrosis-4 score greater than 3.25, suggestive of cirrhosis
